How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?

Sahar Saeed, Erin C Strumpf, Sharon L Walmsley, Kathleen Rollet-Kurhajec, Neora Pick, Valerie Martel-Laferrière, Mark Hull, M John Gill, Joseph Cox, Curtis Cooper, Marina B Klein, Canadian Co-Infection Cohort Study, Jeff Cohen, Brian Conway, Curtis Cooper, Pierre Côté, Joseph Cox, John Gill, Shariq Haider, Marianne Harris, David Haase, Mark Hull, Julio Montaner, Erica Moodie, Neora Pick, Anita Rachlis, Danielle Rouleau, Roger Sandre, Joseph Mark Tyndall, Marie-Louise Vachon, Sharon Walmsley, David Wong, Sahar Saeed, Erin C Strumpf, Sharon L Walmsley, Kathleen Rollet-Kurhajec, Neora Pick, Valerie Martel-Laferrière, Mark Hull, M John Gill, Joseph Cox, Curtis Cooper, Marina B Klein, Canadian Co-Infection Cohort Study, Jeff Cohen, Brian Conway, Curtis Cooper, Pierre Côté, Joseph Cox, John Gill, Shariq Haider, Marianne Harris, David Haase, Mark Hull, Julio Montaner, Erica Moodie, Neora Pick, Anita Rachlis, Danielle Rouleau, Roger Sandre, Joseph Mark Tyndall, Marie-Louise Vachon, Sharon Walmsley, David Wong

Abstract

Background: Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) have been described as revolutionary. However, it remains uncertain how effective these drugs will be for individuals coinfected with human immunodeficiency virus (HIV)-HCV. Bridging this gap between efficacy and effectiveness requires a focus on the generalizability of clinical trials.

Methods: Generalizability of DAA trials was assessed by applying the eligibility criteria from 5 efficacy trials: NCT01479868, PHOTON-1 (NCT01667731), TURQUOISE-I (NCT01939197), ION-4 (NCT02073656), and ALLY-2 (NCT02032888) that evaluated simeprevir; sofosbuvir; ombitasvir, paritaprevir/ritonavir/dasabuvir; sofosbuvir/ledipasvir; and daclatasvir/sofosbuvir, respectively, to the Canadian Coinfection Cohort, representing approximately 23% of the total coinfected population in care in Canada.

Results: Of 874 active participants, 70% had chronic HCV, of whom 410, 26, 94, and 11 had genotypes 1, 2, 3, and 4, respectively. After applying trial eligibility criteria, only 5.9% (24/410) would have been eligible for enrollment in the simeprevir trial, 9.8% (52/530) in PHOTON-1, 6.3% (26/410) in TURQUOISE-I, and 8.1% (34/421) in ION-4. The ALLY-2 study was more inclusive; 43% (233/541) of the cohort would have been eligible. The most exclusive eligibility criteria across all trials with the exception of ALLY-2 were restriction to specific antiretroviral therapies (63%-79%) and active illicit drug use (53%-55%).

Conclusions: DAA trial results may have limited generalizability, since the majority of coinfected individuals were not eligible to participate. Exclusions appeared to be related to improving treatment outcomes by not including those at higher risk of poor adherence and reinfection--individuals for whom real-world data are urgently needed.

Keywords: HIV–hepatitis C coinfection; clinical trials; direct-acting antivirals; generalizability; people who inject drugs.

© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Green figures represent the number of Canadian Coinfection Cohort participants who would be eligible to be screened in NCT01479868 (trial evaluating simeprevir); PHOTON-1: NCT01667731 (trial evaluating sofosbuvir); TURQUOISE-I: NCT01939197 (trial evaluating ombitasvir, paritaprevir/ritonavir/dasabuvir [3D]); ION-4: NCT02073656 (trial evaluating ledipasvir/sofosbuvir); and ALLY-2: NCT02032888 (trial evaluating daclatasvir/sofosbuvir). Gray figures represent participants whose only exclusion was specific antiretroviral (ARV) therapies. Red figures represent participants not eligible regardless of ARV restriction.

References

    1. Soriano V, Barreiro P, Sherman KE. The changing epidemiology of liver disease in HIV patients. AIDS Rev 2013; 15:25–31.
    1. Weber R, Sabin CA, Friis-Moller N et al. . Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632–41.
    1. Salmon-Ceron D, Rosenthal E, Lewden C et al. . Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national mortality 2005 study. J Hepatol 2009; 50:736–45.
    1. Klein MB, Rollet KC, Saeed S et al. . HIV and hepatitis C virus in Canada: challenges and opportunities for reducing preventable morbidity and mortality. HIV Med 2013; 14:10–20.
    1. Labarga P, Soriano V, Vispo ME et al. . Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196:670–6.
    1. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438–50.
    1. Limketkai BN, Mehta SH, Sutcliffe CG et al. . Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370–8.
    1. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008; 59:473–85.
    1. Young J, Potter M, Cox J et al. . Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfected with HIV: a prospective cohort study. CMAJ Open 2013; 1:E106–14.
    1. Jacobson IM, Dore GJ, Foster GR et al. . Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384:403–13.
    1. Molina JM, Orkin C, Iser DM et al. . Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015; 385:1098–106.
    1. Afdhal N, Zeuzem S, Kwo P et al. . Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889–98.
    1. Lawitz E, Mangia A, Wyles D et al. . Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878–87.
    1. Poordad F, Hezode C, Trinh R et al. . ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973–82.
    1. Ferenci P, Bernstein D, Lalezari J et al. . ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983–92.
    1. Manns M, Pol S, Jacobson IM et al. . All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384:1597–605.
    1. Sulkowski MS, Eron JJ, Wyles D et al. . Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223–31.
    1. Naggie S, Cooper C, Saag M et al. . Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:705–13.
    1. Wyles DL, Ruane PJ, Sulkowski MS et al. . Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:714–25.
    1. Soriano V, Labarga P, Vispo E, Fernandez-Montero JV, Barreiro P. Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era. Infect Dis Clin North Am 2012; 26:931–48.
    1. Davies A, Singh KP, Shubber Z et al. . Treatment outcomes of treatment-naive hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PloS One 2013; 8:e55373.
    1. Sulkowski MS, Naggie S, Lalezari J et al. . Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353–61.
    1. Dieterich D, Rockstroh JK, Orkin C et al. . Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis 2014; 59:1579–87.
    1. Klein MB, Saeed S, Yang H et al. . Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol 2010; 39:1162–9.
    1. Mathes T, Antoine SL, Pieper D. Factors influencing adherence in hepatitis-C infected patients: a systematic review. BMC Infect Dis 2014; 14:203.
    1. Jensen D, O'Leary J, Pockros P, Sherman K. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort (abstract 45). In: AASLD 2014/10/03 ed Vol. 60 Suppl 1 Boston, Massachusetts: Hepatology, 2014:197a–695.
    1. Dieterich D, Bacon B, Flamm S, Kowdley K. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population (abstract 46). In: AASLD 2014/10/03 ed Vol. 60 Suppl 1 Boston, Massachusetts: Hepatology, 2014:197a–695.
    1. Brown RS Jr., O'Leary JG, Reddy KR et al. . Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCV-TARGET. Liver Transpl 2015.
    1. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49:561–73.
    1. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163:215–23.
    1. Chen TY, Jain MK. Treatment of hepatitis C in HIV-infected patients: moving towards an era of all oral regimens. AIDS Patient Care STDS 2015; 29:329–37.
    1. Rockstroh JK, Nelson M, Katlama C et al. . Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2:e319–27.
    1. D'Agostino RB Jr., D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA 2007; 297:314–6.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel